SMT201600222B - Formulazione di anticorpi - Google Patents

Formulazione di anticorpi

Info

Publication number: SMT201600222B
Authority: SM; San Marino
Prior art keywords: antibodies; formulation
Prior art date: 2008-12-10

Application number

SM201600222T

Other languages

English (en)

Inventor

Joachim Momm

Hans-Joachim Wallny

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-10

Filing date

2016-07-11

Publication date

2016-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600222(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-07-11 Application filed by Novartis Ag filed Critical Novartis Ag

2016-08-31 Publication of SMT201600222B publication Critical patent/SMT201600222B/it

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Mycology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Dermatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

SM201600222T 2008-12-10 2016-07-11 Formulazione di anticorpi SMT201600222B (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08170884A EP2196476A1 (en)	2008-12-10	2008-12-10	Antibody formulation
EP09764858.8A EP2376533B1 (en)	2008-12-10	2009-12-09	Antibody formulation
PCT/EP2009/066675 WO2010066762A1 (en)	2008-12-10	2009-12-09	Antibody formulation

Publications (1)

Publication Number	Publication Date
SMT201600222B true SMT201600222B (it)	2016-08-31

Family

ID=40637230

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM201600222T SMT201600222B (it)	2008-12-10	2016-07-11	Formulazione di anticorpi

Country Status (31)

Country	Link
US (3)	US20110236398A1 (it)
EP (4)	EP2196476A1 (it)
JP (5)	JP6143416B2 (it)
KR (2)	KR20170044211A (it)
CN (3)	CN102245639B (it)
AU (1)	AU2009324371B2 (it)
BR (1)	BRPI0922730A2 (it)
CA (1)	CA2745938C (it)
CL (1)	CL2011001406A1 (it)
CO (1)	CO6361952A2 (it)
CY (2)	CY1117735T1 (it)
DK (2)	DK2376533T3 (it)
EC (1)	ECSP11011192A (it)
ES (2)	ES2900624T3 (it)
HR (2)	HRP20160754T1 (it)
HU (2)	HUE028408T2 (it)
IL (3)	IL264316B2 (it)
LT (1)	LT3072906T (it)
MA (1)	MA33023B1 (it)
MX (1)	MX2011006242A (it)
MY (2)	MY166050A (it)
NZ (1)	NZ592918A (it)
PE (1)	PE20120342A1 (it)
PL (2)	PL2376533T3 (it)
PT (2)	PT2376533T (it)
RU (2)	RU2745601C2 (it)
SI (2)	SI2376533T1 (it)
SM (1)	SMT201600222B (it)
TN (1)	TN2011000229A1 (it)
WO (1)	WO2010066762A1 (it)
ZA (1)	ZA201103362B (it)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2196476A1 (en) *	2008-12-10	2010-06-16	Novartis Ag	Antibody formulation
US8221753B2 (en)	2009-09-30	2012-07-17	Tracon Pharmaceuticals, Inc.	Endoglin antibodies
RS61082B1 (sr)	2010-02-26	2020-12-31	Novo Nordisk As	Stabilno antitelo koje sadrži kompozicije
SI3345615T1 (sl)	2010-03-01	2020-03-31	Bayer Healthcare Llc	Optimizirana monoklonska protitelesa proti zaviralcu poti tkivnega faktorja (TFPI)
CN105055306B (zh)	2010-05-28	2019-10-01	诺沃—诺迪斯克有限公司	包含抗体和防腐剂的稳定的多剂量组合物
AR082319A1 (es) *	2010-07-22	2012-11-28	Biomarin Pharm Inc	Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
US8822663B2 (en)	2010-08-06	2014-09-02	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
MX351706B (es)	2010-09-17	2017-10-25	Baxalta Inc	Estabilizacion de inmunoglobulinas a traves de una formulacion acuosa con histidina a ph acido debil a neutro.
DE19177059T1 (de)	2010-10-01	2021-10-07	Modernatx, Inc.	N1-methyl-pseudouracile enthältendes ribonucleinsäuren sowie ihre verwendungen
AR085911A1 (es)	2011-03-16	2013-11-06	Sanofi Sa	Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
DE12722942T1 (de)	2011-03-31	2021-09-30	Modernatx, Inc.	Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
KR20190099538A (ko)	2011-10-03	2019-08-27	모더나 세라퓨틱스, 인코포레이티드	변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
FI123630B (fi)	2011-10-24	2013-08-30	Teknologian Tutkimuskeskus Vtt	Menetelmä NFC-kalvojen valmistamiseksi alustoille
US20140348848A1 (en)	2011-12-02	2014-11-27	Dhananjay Kaul	Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
EP2791160B1 (en)	2011-12-16	2022-03-02	ModernaTX, Inc.	Modified mrna compositions
EP2814468B1 (en) *	2012-02-16	2019-06-19	Santarus, Inc.	Anti-vla1 (cd49a) antibody pharmaceutical compositions
ES2737990T3 (es) *	2012-03-16	2020-01-17	Regeneron Pharma	Roedores que expresan secuencias de inmunoglobulina sensibles al pH
CA2868393A1 (en)	2012-04-02	2013-10-10	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of oncology-related proteins and peptides
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en)	2012-04-02	2018-01-30	Modernatx, Inc.	Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US8613919B1 (en)	2012-08-31	2013-12-24	Bayer Healthcare, Llc	High concentration antibody and protein formulations
US8883979B2 (en) *	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
UA115789C2 (uk)	2012-09-05	2017-12-26	Трейкон Фармасутікалз, Інк.	Композиція антитіла до cd105 та її застосування
KR20240091288A (ko) *	2012-09-20	2024-06-21	모르포시스 아게	류마티스 관절염에 대한 치료
WO2014078502A1 (en) *	2012-11-16	2014-05-22	Novartis Ag	Use of il-1 beta binding antibodies for treating peripheral arterial disease
SI2922554T1 (sl)	2012-11-26	2022-06-30	Modernatx, Inc.	Terminalno modificirana RNA
CN105025925A (zh) *	2013-03-15	2015-11-04	拜尔健康护理有限责任公司	抗-催乳素受体抗体制剂
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
TWI679019B (zh)	2013-04-29	2019-12-11	法商賽諾菲公司	抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) *	2013-05-17	2014-11-24	Ablynx Nv	Stable formulations of immunoglobulin single variable domains and uses thereof.
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt)	2013-10-03	2017-09-12	Moderna Therapeutics Inc	polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
JP6707469B2 (ja) *	2014-05-28	2020-06-10	ノノインコーポレイテッド	アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
WO2016034648A1 (en) *	2014-09-03	2016-03-10	Medimmune Limited	Stable anti-il-4r-alpha antibody formulation
AU2015346444A1 (en)	2014-11-12	2017-05-04	Tracon Pharmaceuticals, Inc.	Anti-endoglin antibodies and uses thereof
US9926375B2 (en)	2014-11-12	2018-03-27	Tracon Pharmaceuticals, Inc.	Anti-endoglin antibodies and uses thereof
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es)	2015-06-17	2017-08-16	Lilly Co Eli	Formulación de anticuerpo anti-cgrp
KR102697026B1 (ko) *	2015-12-07	2024-08-20	메르크 파텐트 게엠베하	항-pd-l1 항체 아벨루맙을 포함하는 수성 약학 제형
AU2017289085B2 (en) *	2016-06-27	2024-07-18	Incyte Corporation	Anti-CD19 antibody formulations
KR20190032436A (ko) *	2016-07-21	2019-03-27	노파르티스 아게	폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도
JP2019534863A (ja) *	2016-09-27	2019-12-05	フレゼニウスカービドイチュラントゲーエムベーハー	液体医薬組成物
ES2913401T3 (es)	2016-11-18	2022-06-02	Astellas Pharma Inc	Nuevo fragmento Fab de anticuerpo anti-MUC1 humana
AU2018287519B2 (en) *	2017-06-22	2021-07-22	Novartis Ag	IL-1beta binding antibodies for use in treating cancer
TWI795415B (zh)	2017-07-07	2023-03-11	日商安斯泰來製藥股份有限公司	新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
WO2019053591A1 (en) *	2017-09-13	2019-03-21	Novartis Ag	USE OF IL-1B BINDING ANTIBODIES FOR THE TREATMENT OF ALCOHOLIC HEPATITIS
EP3768706A1 (en) *	2018-03-23	2021-01-27	AbbVie Deutschland GmbH & Co. KG	Stable aqueous anti-tau antibody formulations
KR20210011941A (ko)	2018-05-17	2021-02-02	아스텔라스세이야쿠 가부시키가이샤	항인간 MUC1 항체 Fab 프래그먼트, 펩티드 링커 및/또는 배위자를 포함하는 복합체
CA3115747A1 (en) *	2018-10-10	2020-04-16	Astellas Pharma Inc.	Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CN120241997A (zh) *	2019-02-18	2025-07-04	伊莱利利公司	治疗性抗体制剂
CN113967195A (zh) *	2020-07-22	2022-01-25	三生国健药业（上海）股份有限公司	抗her2/pd1双特异性抗体冻干制剂及其制备方法
US20240052026A1 (en) *	2020-12-22	2024-02-15	Bio-Thera Solutions, Ltd.	Stable antibody formulation, preparation method therefor, and applications thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995001997A1 (en)	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es)	1995-01-23	1997-01-28	Hoffmann La Roche	Proteina accesoria del receptor de la interleucina 1
JPH11510170A (ja)	1995-07-27	1999-09-07	ジェネンテックインコーポレーテッド	タンパク質の処方
US6171586B1 (en) *	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
GB0001662D0 (en)	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
TWI260321B (en)	1999-09-22	2006-08-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
MXPA02012867A (es) *	2000-06-29	2003-09-05	Abbott Lab	Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
US20040038878A1 (en) *	2000-08-04	2004-02-26	Masahiko Tanikawa	Injectable protein formulations
GB0020685D0 (en)	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
ATE556591T1 (de) *	2001-11-08	2012-05-15	Abbott Biotherapeutics Corp	Stabile pharmazeutische flüssigformulierung von igg-antikörpern
US7132100B2 (en) *	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
JP4869064B2 (ja) *	2003-04-04	2012-02-01	ジェネンテック，インコーポレイテッド	高濃度抗体及びタンパク質製剤
CA2595380A1 (en) *	2005-01-28	2006-08-03	Wyeth	Stabilized liquid polypeptide formulations
GT200600031A (es) *	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
MX2007010971A (es) *	2005-03-08	2007-09-19	Pharmacia & Upjohn Co Llc	Composiciones de anticuerpo anti-citla-4.
WO2006125207A2 (en) *	2005-05-19	2006-11-23	Amgen Inc.	Compositions and methods for increasing the stability of antibodies
PT1940465E (pt)	2005-10-26	2012-10-03	Novartis Ag	Nova utilização para compostos de il-1 beta
CN201044845Y (zh) *	2006-10-28	2008-04-09	李开元	自动注射器
RU2009126420A (ru) *	2006-12-11	2011-01-20	Ф.Хоффманн-Ля Рош Аг (Ch)	Парентеральная лекарственная форма антитела к абета
EP2136839A4 (en) *	2007-03-22	2010-04-07	Imclone Llc	STABLE ANTIBODY FORMULATIONS
EP2196476A1 (en) *	2008-12-10	2010-06-16	Novartis Ag	Antibody formulation
WO2010100179A2 (en)	2009-03-05	2010-09-10	Novartis Ag	Self-forming gel system for sustained drug delivery
WO2012028683A1 (en)	2010-09-02	2012-03-08	Novartis Ag	Antibody gel system for sustained drug delivery

2008
- 2008-12-10 EP EP08170884A patent/EP2196476A1/en not_active Ceased
2009
- 2009-12-09 HU HUE09764858A patent/HUE028408T2/en unknown
- 2009-12-09 PT PT97648588T patent/PT2376533T/pt unknown
- 2009-12-09 KR KR1020177009939A patent/KR20170044211A/ko not_active Ceased
- 2009-12-09 CN CN200980149644.4A patent/CN102245639B/zh active Active
- 2009-12-09 MA MA33984A patent/MA33023B1/fr unknown
- 2009-12-09 EP EP16162699.9A patent/EP3072906B1/en active Active
- 2009-12-09 CN CN202111066425.9A patent/CN114225022A/zh active Pending
- 2009-12-09 PE PE2011001179A patent/PE20120342A1/es active IP Right Grant
- 2009-12-09 IL IL264316A patent/IL264316B2/en unknown
- 2009-12-09 LT LTEP16162699.9T patent/LT3072906T/lt unknown
- 2009-12-09 DK DK09764858.8T patent/DK2376533T3/en active
- 2009-12-09 HR HRP20160754TT patent/HRP20160754T1/hr unknown
- 2009-12-09 US US13/133,843 patent/US20110236398A1/en not_active Abandoned
- 2009-12-09 EP EP20197506.7A patent/EP3792282A1/en active Pending
- 2009-12-09 SI SI200931459A patent/SI2376533T1/sl unknown
- 2009-12-09 DK DK16162699.9T patent/DK3072906T3/da active
- 2009-12-09 NZ NZ592918A patent/NZ592918A/xx unknown
- 2009-12-09 KR KR1020117015821A patent/KR101762966B1/ko active Active
- 2009-12-09 BR BRPI0922730A patent/BRPI0922730A2/pt not_active Application Discontinuation
- 2009-12-09 CN CN201410730219.7A patent/CN104399076B/zh active Active
- 2009-12-09 RU RU2015132431A patent/RU2745601C2/ru not_active Application Discontinuation
- 2009-12-09 AU AU2009324371A patent/AU2009324371B2/en active Active
- 2009-12-09 ES ES16162699T patent/ES2900624T3/es active Active
- 2009-12-09 HU HUE16162699A patent/HUE056626T2/hu unknown
- 2009-12-09 SI SI200932153T patent/SI3072906T1/sl unknown
- 2009-12-09 ES ES09764858.8T patent/ES2579835T3/es active Active
- 2009-12-09 JP JP2011540063A patent/JP6143416B2/ja active Active
- 2009-12-09 MY MYPI2014002791A patent/MY166050A/en unknown
- 2009-12-09 MY MYPI2011002067A patent/MY157772A/en unknown
- 2009-12-09 MX MX2011006242A patent/MX2011006242A/es active IP Right Grant
- 2009-12-09 HR HRP20211899TT patent/HRP20211899T1/hr unknown
- 2009-12-09 CA CA2745938A patent/CA2745938C/en active Active
- 2009-12-09 WO PCT/EP2009/066675 patent/WO2010066762A1/en active Application Filing
- 2009-12-09 RU RU2011127913/15A patent/RU2563179C2/ru active
- 2009-12-09 EP EP09764858.8A patent/EP2376533B1/en active Active
- 2009-12-09 PL PL09764858.8T patent/PL2376533T3/pl unknown
- 2009-12-09 PL PL16162699T patent/PL3072906T3/pl unknown
- 2009-12-09 PT PT161626999T patent/PT3072906T/pt unknown
2011
- 2011-05-09 ZA ZA2011/03362A patent/ZA201103362B/en unknown
- 2011-05-10 TN TN2011000229A patent/TN2011000229A1/fr unknown
- 2011-05-16 IL IL212922A patent/IL212922B/en active IP Right Grant
- 2011-06-09 CL CL2011001406A patent/CL2011001406A1/es unknown
- 2011-06-10 CO CO11072271A patent/CO6361952A2/es not_active Application Discontinuation
- 2011-07-08 EC EC2011011192A patent/ECSP11011192A/es unknown
2012
- 2012-08-15 US US13/586,185 patent/US8623367B2/en active Active
2015
- 2015-07-01 JP JP2015132999A patent/JP2015231997A/ja not_active Withdrawn
2016
- 2016-06-30 CY CY20161100603T patent/CY1117735T1/el unknown
- 2016-07-11 SM SM201600222T patent/SMT201600222B/it unknown
2018
- 2018-05-29 JP JP2018102715A patent/JP2018168158A/ja not_active Withdrawn
2020
- 2020-07-16 US US16/930,475 patent/US20200384108A1/en active Pending
- 2020-08-06 JP JP2020133477A patent/JP7286595B2/ja active Active
- 2020-08-10 IL IL276622A patent/IL276622A/en unknown
2021
- 2021-12-07 CY CY20211101069T patent/CY1124844T1/el unknown
2023
- 2023-05-24 JP JP2023085464A patent/JP2023109938A/ja active Pending

Also Published As

Publication number	Publication date
ES2579835T3 (es)	2016-08-17
DK3072906T3 (da)	2021-12-13
IL264316A (en)	2019-02-28
EP3072906A1 (en)	2016-09-28
LT3072906T (lt)	2021-12-27
MX2011006242A (es)	2011-06-24
CY1124844T1 (el)	2022-11-25
HRP20160754T1 (hr)	2016-08-12
SI3072906T1 (sl)	2022-01-31
PT2376533T (pt)	2016-07-13
CN102245639B (zh)	2014-12-24
RU2015132431A (ru)	2018-12-24
KR101762966B1 (ko)	2017-07-31
CN104399076A (zh)	2015-03-11
CL2011001406A1 (es)	2012-03-30
ECSP11011192A (es)	2011-08-31
CA2745938A1 (en)	2010-06-17
AU2009324371B2 (en)	2013-10-10
US20110236398A1 (en)	2011-09-29
MY157772A (en)	2016-07-29
NZ592918A (en)	2012-12-21
AU2009324371A1 (en)	2011-06-23
ZA201103362B (en)	2012-01-25
JP2023109938A (ja)	2023-08-08
HUE056626T2 (hu)	2022-02-28
EP3072906B1 (en)	2021-09-08
JP6143416B2 (ja)	2017-06-07
CN104399076B (zh)	2021-09-14
RU2011127913A (ru)	2013-01-20
IL276622A (en)	2020-09-30
PL2376533T3 (pl)	2016-09-30
CO6361952A2 (es)	2012-01-20
JP2020203889A (ja)	2020-12-24
JP2015231997A (ja)	2015-12-24
RU2563179C2 (ru)	2015-09-20
EP2376533B1 (en)	2016-03-30
US20200384108A1 (en)	2020-12-10
HRP20211899T1 (hr)	2022-03-04
PT3072906T (pt)	2021-12-14
MA33023B1 (fr)	2012-02-01
EP3792282A1 (en)	2021-03-17
IL264316B2 (en)	2024-01-01
JP2018168158A (ja)	2018-11-01
ES2900624T3 (es)	2022-03-17
KR20120009421A (ko)	2012-01-31
WO2010066762A1 (en)	2010-06-17
PL3072906T3 (pl)	2022-01-24
KR20170044211A (ko)	2017-04-24
CY1117735T1 (el)	2017-05-17
TN2011000229A1 (en)	2012-12-17
JP2012511540A (ja)	2012-05-24
RU2015132431A3 (it)	2018-12-24
CN102245639A (zh)	2011-11-16
BRPI0922730A2 (pt)	2018-11-06
PE20120342A1 (es)	2012-04-24
JP7286595B2 (ja)	2023-06-05
EP2196476A1 (en)	2010-06-16
MY166050A (en)	2018-05-22
CN114225022A (zh)	2022-03-25
HK1159130A1 (zh)	2012-07-27
IL212922B (en)	2019-02-28
IL212922A0 (en)	2011-07-31
RU2745601C2 (ru)	2021-03-29
US8623367B2 (en)	2014-01-07
SI2376533T1 (sl)	2016-07-29
IL264316B1 (en)	2023-09-01
CA2745938C (en)	2018-04-24
US20120315285A1 (en)	2012-12-13
HUE028408T2 (en)	2016-12-28
DK2376533T3 (en)	2016-06-27
EP2376533A1 (en)	2011-10-19

Publication	Publication Date	Title
SMT201600222B (it)	2016-08-31	Formulazione di anticorpi
EP2358392A4 (en)	2012-08-29	ANTIBODY FORMULATION
DK2459167T3 (da)	2013-06-03	SUBKUTAN ANTI-HER2-antistofformulering
BRPI1006519A2 (pt)	2016-08-09	formulação de anticorpos
DK2234600T3 (da)	2014-09-08	Antistofformulering
BRPI0917888A2 (pt)	2014-02-25	Formulação de anticorpo líquida estável
EP2254911A4 (en)	2011-10-19	HUMANIZED ANTI-C5aR ANTIBODIES
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
EP2262831A4 (en)	2012-07-25	ANTI-properdin antibody
BRPI0912026A2 (pt)	2015-10-06	formulação homeopática
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
BRPI0918419A2 (pt)	2015-11-24	nova formulação anticorpo
EP2207803A4 (en)	2010-11-24	Cd9-specific human antibodies
BRPI1009465A2 (pt)	2015-08-18	Formulação
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
EP2350385A4 (en)	2012-05-02	Forming section
EP2426149A4 (en)	2013-01-23	ANTI-CADHERIN ANTIBODY
BRPI0912769A2 (pt)	2015-10-13	anticorpos anti-pirb
ITTO20110268A1 (it)	2011-09-30	Composizione di maquillage.
CU23884B1 (es)	2013-04-19	Derivados de dibenzotiazepina
BRPI0909840A2 (pt)	2015-07-28	Uso de 4-tio-2-deoxinucleosídios
EP2424892A4 (en)	2012-12-19	DC-STAMP ANTIBODY
SMT201500123B (it)	2015-09-07	Dosaggio unitario di apadenoson